Abstract:
A tandem strategy for the synthesis of 7,12-dihydro-1,3,6,7,12-pentaazapleiadenes and 4-(2-aminophenoxy)pyrido[4,3-d]pyrimidin-5(6H)-ones from readily available starting materials has been developed.
Introduction
Nitrogen containing heteroaryl moieties are present in a large number of pharmaceutically relevant and biologically active compounds [1]. Cyclic nitrogen-linked biaryls represent a therapeutically important motif in medicinal chemistry. In particular, seven-membered N-linked biaryl scaffolds have been known to show a wide range of biological properties [2, 3]. Oxcarbazepine (1) shows antiepileptic activity [4], and olanzapine (2) and clozaopine (3) exhibit strong antipsychotic activity [5, 6]. These three compounds have a common seven-membered ring-linked biaryl (Figure 1). 7-Azasampangine (4), with a six-membered N-linked biaryl backbone is an antimicrobial agent [7]. We envisaged that tetracyclic pentaazapleiadene (10) having a seven-membered N-linked biaryl scaffold could be exploited to elicit enhanced biological activity similar to that of 7-azasampangine (4) or clozaopine (3).

Biologically active compounds 1–4 and 10.
Results and discussion
We have recently reported a novel methodology involving an acid-mediated domino reaction to build tetracyclic 7-azasampangine (4) [8]. We have utilized this domino methodology to build the complex tetracyclic pentaazapleiadene (10). In this methodology, stannous chloride not only reduces the nitro group but also provides the acidic environment required to facilitate the domino reaction.
(Z)-3-Amino-2-cyanobut-2-enamide (5) was obtained by condensation of cyanoacetamide and acetamidine hydrochloride under basic conditions [9]. Treatment of the enamide (5) with triethyl orthoformate and acetic anhydride yielded 4-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (6) [9]. Compound 6 was treated with POCl3 to give 4-chloro-6-methylpyrimidine-5-carbonitrile (7) [10, 11]. Compound 7 is a key intermediate for the current methodology. Compound 7 was reacted with various 4-substituted 2-nitroanilines to produce the trisubstituted pyrimidine intermediates 8a–j. By contrast, intermediate products 11a–f were obtained by reacting compound 7 with various 4-substituted 2-nitrophenols. The enamines 9a–j and 12a–f were obtained by reaction of 8a–j and 11a–f with dimethylformamide-dimethylacetal (DMF-DMA) [12, 13]. In this reaction, a proton from the benzylic methyl group is removed by DMF-DMA and a molecule of methanol is eliminated resulting in the formation of an activated benzylic methylene function and methoxymethylene imidinium ion. The activated benzylic methylene group traps the imidinium ion, and the subsequent elimination of another molecule of methanol results in the formation of enamine [13].
Compounds 9a–j, with 2-nitroaniline, a nitrile, and enamine functional groups on the consecutive carbon atoms of the pyrimidine ring, are the key functionalities that undergo the domino reaction upon treatment with anhydrous SnCl2 in dry tetrahydrofuran (THF). In this transformation, after nitro reduction, two C-N bonds are formed in one pot to yield the tetracyclic pentaazapleiadenes 10a–j (Scheme 1). The tetracyclic pentaazapleiadene derivatives were obtained in good yields in the case of various 4-substituted 2-nitroanilines. However, when 4-substituted 2-nitrophenols were used in place of the 2-nitroanilines in the presence of anhydrous SnCl2 in dry THF, the corresponding 2-aminoenamine derivatives 13a–f were obtained (Scheme 2). When compounds 12a–f were treated with SnCl2×2H2 O in dry THF, the corresponding aminopyridopyrimidinone derivatives 14a–f were formed (Scheme 2).

Synthesis of 9-substituted 7,12-dihydro-1,3,6,7,12-pentaazapleiadenes. Reagents and conditions: (i) acetamidine hydrochloride (1 equiv.), Na (1 equiv.), EtOH, at 0°C to rt (24 h), reflux, 2 h; (ii) HC(OEt)3 (10 mL/g), (CH3 CO)2 O (10 mL/g), 140°C, 3.5 h; (iii) Et3 N (0.2 equiv.), POCl3 (1 equiv.), toluene, 100°C, 12 h; (iv) neat 130°C, 0.5 h; (v) DMF-DMA, 130°C, 3.5 h; (vi) anhydrous SnCl2 (5 equiv.) or SnCl2×2H2 O (5 equiv.), dry THF, reflux, 18 h.

Synthesis of 13 and 14. Reagents and conditions: (i) K2 CO3 (2 equiv.), DMF, rt, 0.5 h; (ii) DMF-DMA, 130°C, 3.5 h; (iii) anhydrous SnCl2 (5 equiv.), dry THF, reflux, 6 h; (iv) SnCl2×2H2 O (5 equiv.), dry THF, reflux, 18 h.
The acid catalyzed domino reaction to give the tetracyclic pentaazapleiadenes 10a–j may be explained by the mechanism proposed in Scheme 3. Under acidic conditions, protonation of the β-carbon of the dimethylaminoenamine group generates an iminium ion [14]. The iminium cation is involved in a cascade of electron transfers, from the newly formed amino group to the cyano group that finally leads to quenching of the positive charge in the iminium ion, thereby resulting in the formation of two C-N bonds. The elimination of dimethylamine gives the tetracyclic pentaazapleiadenes. Similar transformations were earlier exploited for the synthesis of diazapines and azaphenalenes [15]. However, analogous domino transformations were not observed for compounds 12a–f, possibly due to the electronegative nature of the oxygen atom ortho to the anilinic amino group.

Proposed mechanism for the formation of 7,12-dihydro-1,3,6,7,12-pentaazapleiadene.
Conclusion
A variety of tetracyclic pentaazapleiadenes utilizing our domino methodology [8] were synthesized. In this methodology, stannous chloride plays the dual role of reducing the nitro group and providing the necessary acidic conditions to trigger the domino reaction.
Experimental
THF was dried with sodium and distilled. All other solvents and reagents were used as received. Melting points were determined on a Buchi melting point B-540 apparatus. The 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were obtained on a Varian 400 spectrometer in DMSO-d6. Mass spectra were obtained on an API 2000 Perkin Elmer (PE-SCIEX) mass spectrometer. IR spectra were recorded on an IR Prestage-21 FTIR spectrometer using KBr pellets. High resolution mass spectra were recorded in a positive ESI mode on a quadrupole time-of-flight (Q-TOF) mass spectrometer (Q-TOF, LC/MS 6510 series classic G6510A, Agilent Technologies, USA). The data acquisition was controlled by Mass Hunter workstation software.
General procedure for the preparation of 4-methyl-6-[(2-nitrophenyl)amino]pyrimidine-5-carbonitrile derivatives 8a–j
A mixture of 4-chloro-6-methylpyrimidine-5-carbonitrile (7) (6.54 mmol) and 2-nitroaniline (6.23 mmol) was heated at 130°C for 30 min. After cooling to room temperature, the reaction mixture was treated with 50 mL of water, basified with saturated sodium carbonate solution to ∼pH 9, stirred for 20 min, and then extracted with ethyl acetate. The extract was successively washed with water and brine, dried (Na2 SO4), and concentrated.
4-[(4-Methoxy-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8a)
Yield 72% (1500 mg); orange solid; mp 186–188°C; IR: 3259, 2918, 2833, 2218, 1604, 1556, 1519, 1334, 1236, 1024, 858 cm-1; 1H NMR: δ 10.02 (s, 1H), 8.48 (s, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 3 Hz, 1H), 7.35 (dd, J1 = 8.8 Hz, J2 =3 Hz, 1H), 3.87 (s, 3H), 2.54 (s, 3H); MS (ESI): m/z 286 (M+H]+; HRMS (ESI): m/z calcd for C13 H12 N5 O3+ [M+H]+ 286.0935, found 286.0901.
4-[(4-Ethyl-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8b)
Yield 74% (850 mg); yellow solid; mp 138–140°C; 1H NMR: δ 10.22 (s, 1H), 8.53 (s, 1H), 7.91 (d, J = 2 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.62 (dd, J1 = 8.4 Hz, J2 = 2 Hz, 1H), 2.72 (q, J = 7.2 Hz, 2H), 2.56 (s, 3H), 1.22 (t, J = 7.2 Hz, 3H); HRMS (ESI): m/z calcd for C14 H14 N5 O2+ [M+H]+ 284.1165, found 284.1161.
4-[(4-(Tert-butyl)-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8c)
Yield 79% (500 mg); yellow solid; mp 170–172°C; 1H NMR: δ 10.21 (s, 1H), 8.52 (s, 1H), 7.98 (d, J = 2 Hz, 1H), 7.82 (dd, J1 = 8.8 Hz, J2 = 2 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 2.56 (s, 3H), 1.33 (s, 9H); HRMS (ESI): m/z calcd for C16 H18 N5 O2+ [M+H]+ 312.1455, found 312.1464.
4-Methyl-6-[(4-methyl-2-nitrophenyl)amino]pyridine-5-carbonitrile (8d)
Yield 72% (1000 mg); pale brown solid; mp 205–207°C; 1H NMR: δ 10.18 (br s, 1H), 8.54 (s, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.58 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H), 2.56 (s, 3H), 2.49 (s, 3H); HRMS (ESI): m/z calcd for C13 H12 N5 O2+ [M+H]+ 270.0986, found 270.0985.
4-Methyl-6-[(2-nitrophenyl)amino]pyrimidine-5-carbonitrile (8e)
Yield 74% (1200 mg); yellow solid; mp 172–174°C; 1H NMR: δ 10.30 (s, 1H), 8.55 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.84–7.75 (m, 2H), 7.47(m, 1H), 2.57 (s, 3H); HRMS (ESI): m/z calcd for C12 H10 N5 O2+ [M+H]+ 256.0829, found 256.0823.
4-[(4-Isopropyl-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8f)
Yield 72%; (160 mg); yellow solid; mp 123–125°C; 1H NMR: δ 10.30 (s, 1H), 8.55 (s, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.66 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 3.04 (heptet, J = 6.8 Hz, 1H), 2.56 (s, 3H), 1.25 (d, J = 6.8 Hz, 6H); HRMS (ESI): m/z calcd for C15 H16 N5 O2+ [M+H]+ 298.1299, found 298.1282.
4-Methyl-6-[(2-nitro-4-(trifluoromethyl)phenyl]amino)pyrimidine-5-carbonitrile (8g)
Yield 69% (320 mg); pale yellow solid; mp 174–176°C; 1H NMR: δ 10.64 (s, 1H), 8.63 (s, 1H), 8.39 (s, 1H), 8.16 (s, 2H), 2.60 (s, 3H); HRMS (ESI): m/z calcd for C13 H9 N5 O2 F3+ [M+H]+ 324.0703, found 324.0671.
4-[(4-Fluoro-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8h)
Yield 68% (230 mg); pale brown solid; mp 186–188°C; 1H NMR: δ 10.24 (s, 1H), 8.53 (s, 1H), 8.01 (dd, J1 = 8.4 Hz, J2 = 2.8 Hz, 1H), 7.82–7.78 (m, 1H), 7.72–7.68 (m, 1H), 2.56 (s, 3H); HRMS (ESI): m/z calcd for C12 H9 N5 O2 F+ [M+H]+ 274.0735, found 274.0724.
4-[(4-Chloro-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8i)
Yield 65% (1300 mg); yellow solid; mp 206–208°C; 1H NMR: δ 10.39 (s, 1H), 8.57 (s, 1H), 8.16 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.86–7.81 (m, 2H), 2.57 (s, 3H); HRMS (ESI): m/z calcd for C12 H9 N5 O2 Cl+ [M+H]+ 290.0440, found 290.0412.
4-[(4-Bromo-2-nitrophenyl)amino]-6-methylpyrimidine-5-carbonitrile (8j)
Yield 64% (210 mg); yellow solid; mp 210–212°C; 1H NMR: δ 10.33 (s, 1H), 8.56 (s, 1H), 8.25 (d, J = 2.0 Hz, 1H), 7.99 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 2.57 (s, 3H); m/z: 336 HRMS (ESI): m/z calcd for C12 H9 N5 O281Br+ and C12 H9 N5 O279Br+ [M+H]+ 335.9914 and 333.9935, found 335.9846 and 333.9871.
General procedure for the preparation of compounds 9a–j
A solution of a 5-cyano-6-methylpyrimidine (8a–j; 5.88 mmol) and DMF-DMA (147 mmol) was heated under reflux at 130°C for 3.5 h, then cooled and poured into ice water. The resultant solid was filtered and dried under reduced pressure to afford products 9a–j, which were used in the next step without further purification.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(4-methoxy-2-notrophenyl)amino]pyrimidine-5-carbonitrile (9a)
Yield 63% (1000 mg); red solid; mp 196–198°C; IR: 3113, 2933, 2200, 1597, 1531, 1512, 1402, 1278, 1230, 1111, 1031, 839 cm-1; 1H NMR: δ 9.62 (s, 1H), 8.11 (s, 1H), 8.09 (d, J = 12 Hz, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 2.8 Hz, 1H), 7.32 (dd, J1 = 8.8 Hz, J2 = 2.8 Hz, 1H), 5.18 (d, J = 12 Hz, 1H), 3.85 (s, 3H), 3.16 (br s, 3H), 2.91 (br s, 3H); HRMS (ESI): m/z calcd for C16 H17 N6 O3+ [M+H]+ 341.1357, found 341.1409.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(4-ethyl-2-nitrophenyl)amino]pyrimidine-5-carbonitrile (9b)
Yield 58% (350 mg); brown solid; mp 178–180°C; 1H NMR: δ 9.85 (s, 1H), 8.15 (s, 1H), 8.09 (d, J = 11.6 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 2 Hz, 1H), 7.58 (dd, J1 = 8.4 Hz, J2 = 2 Hz, 1H), 5.29 (d, J = 11.6 Hz, 1H), 3.16 (br s, 3H), 2.91 (br s, 3H), 2.68 (q, J = 7.6 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H); HRMS (ESI): m/z calcd for C17 H19 N6 O2+ [M+H]+ 339.1564, found 339.1586.
(E)-4-[(4-(Tert-butyl)-2-nitrophenyl)amino]-6-[2-(dimethylamino)vinyl] pyrimidine-5-carbonitrile (9c)
Yield 60% (300 mg); brown solid; mp 102–104°C; 1H NMR: δ 9.83 (s, 1H), 8.15 (s, 1H), 8.09 (d, J = 12.4 Hz, 1H), 7.95 (d, J = 2 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.78 (dd, J1 = 8.8 Hz, J2 = 2 Hz, 1H), 5.20 (d, J = 12.4 Hz, 1H), 3.16 (br s, 3H), 2.91 (br s, 3H), 1.27 (s, 9H); HRMS (ESI): m/z calcd for C19 H23 N6 O2+ [M+H]+ 367.1877, found 367.1922.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(4-methyl-2-nitrophenyl)amino]pyrimidine-5-carbonitrile (9d)
Yield 62% (130 mg); brown solid; mp 199–201°C; 1H NMR: δ 9.84 (s, 1H), 8.15 (s, 1H), 8.09 (d, J = 12.4 Hz, 1H), 7.90–7.88 (m, 2H), 7.55–7.53 (m, 1H), 5.21 (d, J = 12.4 Hz, 1H), 3.16 (br s, 3H), 2.91 (br s, 3H), 1.37 (s, 3H); HRMS (ESI): m/z calcd for C16 H17 N6 O2+ [M+H]+ 325.1408, found 325.1446.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(2-nitrophenyl)amino]pyrimidine-5-carbonitrile (9e)
Yield 65% (950 mg); brown solid; mp 185–187°C; 1H NMR: δ 9.98 (s, 1H), 8.18 (s, 1H), 8.11 (d, J = 12.4 Hz, 1H), 7.78 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 2H), 7.74–7.70 (m, 1H), 7.36–7.32 (m, 1H), 5.20 (d, J = 12.4 Hz, 1H), 3.17 (br s, 3H), 2.92 (br s, 3H); HRMS (ESI): m/z calcd for C15 H15 N6 O2+ [M+H]+ 311.1251, found 311.1299.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(4-isopropyl-2-nitrophenyl)amino]pyrimidine-5-carbonitrile(9f)
Yield 68% (100 mg); brown solid; mp 126–128°C. 1H NMR: δ 9.85 (s, 1H), 8.15 (s, 1H), 8.09 (d, J = 12.4 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 2 Hz, 1H), 7.62 (dd, J1 = 8.4 Hz, J2 = 2 Hz, 1H), 5.19 (d, J = 12.4 Hz, 1H), 3.16 (br s, 3H), 3.09 (heptet, J = 6.8 Hz, 1H), 2.98 (br s, 3H), 1.23 (d, J = 6.8 Hz, 6H); HRMS (ESI): m/z calcd for C18 H21 N6 O2+ [M+H]+ 353.1721, found 353.1773.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(2-nitro-4-(trifluoromethyl)phenyl)amino]pyrimidine-5-carbonitrile (9g)
Yield 65% (200 mg); pale brown solid; mp 230–232°C; 1H NMR: δ 10.34 (s, 1H), 8.40–8.35 (m, 2H), 8.24 (s, 1H), 8.15 (d, J = 12 Hz, 1H), 8.11–8.06 (m, 1H), 5.23 (d, J = 12 Hz, 1H), 3.19 (br s, 3H), 2.94 (br s, 3H); HRMS (ESI): m/z calcd for C16 H14 F3 N6 O2+ [M+H]+ 379.1125, found 379.1186.
(E)-4-[2-(Dimethylamino)vinyl]-6-[(4-fluoro-2-nitrophenyl)amino]pyrimidine-5-arbonitrile (9h)
Yield 61% (150 mg); brown solid; mp 182–184°C; 1H NMR: δ 9.83 (br s, 1H), 8.25 (s, 1H), 8.08 (d, J = 12 Hz, 1H), 7.99–7.94 (m, 1H), 7.81–7.75 (m, 2H), 5.22 (d, J = 12 Hz, 1H), 3.22 (br s, 3H), 2.97 (br s, 3H); HRMS (ESI): m/z calcd for C15 H14 FN6 O2+ [M+H]+ 329.1157, found 329.1215.
(E)-4-[(4-Chloro-2-nitrophenyl)amino]-6-[2-(dimethylamino)vinyl]pyrimidine-5-carbonitrile (9i)
Yield 57% (150 mg); orange solid; mp 136–138°C; 1H NMR: δ 9.99 (br s, 1H), 8.18 (s, 1H), 8.11 (d, J = 12 Hz, 1H), 8.07–8.05 (m, 1H), 7.86–7.80 (m, 2H), 5.21 (d, J = 12 Hz, 1H), 3.22 (br s, 3H), 2.97 (br s, 3H); HRMS (ESI): m/z calcd for C15 H14 ClN6 O2+ [M+H]+ 345.0861, found 345.0923.
(E)-4-[(4-Bromo-2-nitrophenyl)amino]-6-[2-(dimethylamino)vinyl]pyrimidine-5-carbonitrile (9j)
Yield 52% (110 mg); brown solid; mp 138–140°C; 1H NMR: δ 9.98 (br s, 1H), 8.18 (s, 1H), 8.12 (d, J = 12 Hz, 1H), 8.09–8.01 (m, 1H), 7.69–7.61 (m, 2H), 5.22 (d, J = 12 Hz, 1H), 3.22 (br s, 3H), 2.97 (br s, 3H); HRMS (ESI): m/z calcd for C15 H14 N6 O281Br+ and C15 H14 N6 O279Br+ [M+H]+ 391.0336 and 389.0356, found 391.0403 and 389.0420.
General procedure for preparation of compounds 10a–j
To a solution of enamine 9a–j (4.8 mmol) in dry THF (45 mL) was added anhydrous SnCl2 (24.2 mmol), and the mixture was heated under reflux under inert atmosphere for 18 h. The reaction mixture was cooled and poured into ice-cold water and basified with saturated aqueous sodium carbonate to ∼pH 9. The basic aqueous mixture was extracted with ethyl acetate three times. The ethyl acetate layers were pooled, washed with water, dried over anhydrous Na2 SO4, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (100–200 mesh) eluting with 1–2% (v/v) methanol in dichloromethane.
9-Methoxy-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10a)
Yield 75% (248 mg); pale yellow solid; mp 277–279°C; IR: 3267, 3219, 2953, 2833, 1631, 1593, 1523, 1460, 1334, 1288, 1230, 1122, 891, 833 cm-1; 1H NMR: δ 9.96 (br s, 1H), 9.16 (br s, 1H), 8.60 (s, 1H), 8.23 (d, J = 5.6 Hz, 1H), 7.04 (d, J = 8.8 Hz, 1H), 7.01 (d, J = 5.6 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.46 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 4.02 (s, 3H); 13C NMR: δ 158.7, 157.6, 156.5, 156.3, 154.7, 149.4, 132.9, 122.3, 121.7, 113.3, 107.8, 105.5, 98.1, 55.1; HRMS (ESI): m/z calcd for C14 H11 N5 NaO+ [M+Na]+ 288.0856, found 288.0874.
9-Ethyl-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10b)
Yield 71% (170 mg); pale yellow solid; mp 246–248°C; IR: 3267, 3224, 2964, 2202, 1627, 1600, 1460, 1388, 1334, 1226, 1114, 1055, 825 cm-1; 1H NMR: δ 9.97 (br s, 1H), 9.13 (br s, 1H), 8.62 (s, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 7.00 (d, J = 5.6 Hz, 1H), 6.97 (d, J = 1.6 Hz, 1H), 6.70 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H), 2.50 (t, J = 7.6 Hz, 2H), 1.13 (q, J = 7.6 Hz, 3H); 13C NMR: δ 159.0, 157.6, 156.5, 154.9, 149.5, 139.9, 131.6, 126.9, 122.1, 120.7, 119.2, 113.0, 98.2, 27.3, 15.2; HRMS (ESI): m/z calcd for C15 H14 N5+ [M+H]+ 264.12437, found 264.12383.
9-(Tert-butyl)-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10c)
Yield 72% (100 mg); pale yellow solid; mp 249–251°C; IR: 3271, 3209, 2962, 1631, 1585, 1462, 1384, 1332, 1219, 1120, 1060, 835 cm-1; 1H NMR: δ 9.97 (br s, 1H), 9.10 (br s, 1H), 8.62 (s, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 5.6 Hz, 1H), 6.87 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 1.22 (s, 9H); 13C NMR: δ 159.0, 157.6, 156.5, 154.9, 149.5, 147.1, 131.2, 126.6, 120.4, 119.6, 117.2, 113.0, 98.2, 33.9, 30.9 (3C); HRMS (ESI): m/z calcd for C17 H18 N5+ [M+H]+ 292.15567, found 292.15505.
9-Methyl-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10d)
Yield 68% (50 mg); yellow solid; mp 242–244°C; IR: 3269, 3047, 2962, 1604, 1587, 1452, 1384, 1334, 1228, 1116, 1060, 831 cm-1; 1H NMR: δ 9.97 (br s, 1H), 9.15 (br s, 1H), 8.62 (s, 1H), 8.24 (d, J = 5.6 Hz, 1H), 7.01 (d, J = 5.6 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.87 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 2.16 (s, 3H); 13C NMR: δ 158.9, 157.6, 156.5, 154.8, 149.5, 133.5, 131.5, 126.7, 123.3, 120.7, 120.3, 113.0, 98.1, 20.2; HRMS (ESI): m/z calcd for C14 H12 N5+ [M+H]+ 250.10872, found 250.10834.
7,12-Dihydro-1,3,6,7,12-pentaazapleiadene (10e)
Yield 66% (180 mg); yellow solid; mp 199–201°C; IR: 3273, 3062, 2962, 1631, 1612, 1571, 1392, 1334, 1242, 1116, 1056, 831 cm-1; 1H NMR: δ 10.03 (br s, 1H), 9.27 (br s, 1H), 8.66 (s, 1H), 8.26 (d, J = 5.6 Hz, 1H), 7.12–7.03 (m, 3H), 6.90–6.85 (m, 2H); 13C NMR: δ 159.0, 157.6, 156.5, 154.8, 149.5, 131.7, 129.2, 124.3, 122.7, 120.7, 120.1, 113.0, 98.2; HRMS (ESI): m/z calcd for C13 H10 N5+ [M+H]+ 236.09307, found 236.09286.
9-Isopropyl-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10f)
Yield 68% (40 mg); yellow solid; mp 250–252°C; IR: 3265, 3050, 2960, 1629, 1581, 1452, 1388, 1332, 1226, 1118, 1058, 827 cm-1; 1H NMR: δ 9.97 (br s, 1H), 9.11 (br s, 1H), 8.62 (s, 1H), 8.24 (d, J = 5.2 Hz, 1H), 7.04–7.00 (m, 3H), 6.73 (dd, J1 = 8.4 Hz, J2 =2 Hz, 1H), 2.73 (heptet, J = 6.8 Hz, 1H), 1.15 (d, J = 6.8 Hz, 6H); 13C NMR: δ 159.0, 157.6, 156.5, 154.9, 149.5, 144.7, 131.6, 126.9, 120.7, 120.6, 117.9, 113.0, 98.2, 32.6, 23.6 (2C); HRMS (ESI): m/z calcd for C16 H16 N5+ [M+H]+ 278.14002, found 278.13954.
9-(Trifluoromethyl)-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10g)
Yield 65% (90 mg); pale brown solid; mp 238–240°C; IR: 3224, 3008, 2962, 1625, 1589, 1454, 1328, 1269, 1122, 1068, 883 cm-1; 1H NMR: δ 10.35 (br s, 1H), 9.59 (br s, 1H), 8.74 (s, 1H), 8.31 (d, J = 5.6 Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 5.6 Hz, 1H); 13C NMR: δ 158.3, 157.7, 156.6, 156.2, 153.6, 149.6, 132.5, 124.5, 122.7, 121.4, 119.1, 116.6, 113.6, 98.1; HRMS (ESI): m/z calcd for C14 H9 N5 F3+ [M+H]+ 304.08046, found 304.07996.
9-Fluoro-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10h)
Yield 55% (50 mg); pale brown solid; mp 278–280°C; IR: 3232, 3047, 2212, 1600, 1517, 1386, 1334, 1219, 1163, 1056, 837 cm-1; 1H NMR: δ 10.09 (br s, 1H), 9.40 (br s, 1H), 8.66 (s, 1H), 8.27 (d, J = 5.6 Hz, 1H), 7.15–7.11 (m, 1H), 7.06 (d, J = 5.6 Hz, 1H), 6.99–6.96 (m, 1H), 6.72–6.70 (m, 1H); 13C NMR (100 MHz, DMSO-d6) δ 158.5, 157.7, 156.4, 154.1, 149.4, 133.2, 125.6, 122.0, 121.9, 113.6, 108.9, 106.4, 98.2; HRMS (ESI): m/z calcd for C13 H9 N5 F+ [M+H]+ 254.08365, found 254.08333.
9-Chloro-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10i)
Yield 51% (51 mg); brown solid; mp 204–206°C; IR: 3232, 3047, 2997, 1672, 1581, 1485, 1334, 1217, 1074, 833 cm-1; 1H NMR: δ 10.16 (br s, 1H), 9.43 (br s, 1H), 8.68 (s, 1H), 8.28 (d, J = 5.6 Hz, 1H), 7.19 (s, 1H), 7.13 (d, J = 8.8 Hz, 1H), 7.07 (d, J = 5.6 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H); 13C NMR: δ 158.4, 157.7, 156.3, 153.9, 149.5, 132.9, 128.1, 127.6, 122.0, 119.1, 113.6, 108.9, 98.2; HRMS (ESI): m/z calcd for C13 H9 N5 Cl+ [M+H]+ 270.0541, found 270.0542.
9-Bromo-7,12-dihydro-1,3,6,7,12-pentaazapleiadene (10j)
Yield 46% (28 mg); brown solid; mp 201–203°C; IR: 3230, 3045, 2987, 1658, 1587, 1485, 1334, 1219, 1062, 837 cm-1; 1H NMR: δ 10.17 (br s, 1H), 9.42 (br s, 1H), 8.68 (s, 1H), 8.28 (d, J = 5.6 Hz, 1H), 7.32 (s, 1H), 7.08–7.00 (m, 3H); 13C NMR: δ 158.4, 157.7, 156.3, 154.0, 149.5, 128.5, 127.6, 124.9, 122.3, 121.9, 115.5, 113.5, 98.2; HRMS (ESI): m/z calcd for C13 H9 N581Br+ and C13 H9 N579Br+ [M+H]+ 316.0021 and 314.0036, found 316.0034 and 314.0044.
General procedure for preparation of compounds 11a–f
To a solution of 2-nitrophenol (5.23 mmol) and potassium carbonate (10.46 mmol) in dry DMF (15 mL), 4-chloro-6-methylpyrimidine-5-carbonitrile (7) (5.23 mmol) was added, and the mixture was stirred at room temperature for 30 min. The mixture was treated with 100 mL of water and extracted with ethyl acetate (3×50 mL). The extract was dried over anhydrous Na2 SO4 and evaporated to dryness to furnish the desired product.
4-(4-Methoxy-2-nitrophenoxy)-6-methylpyrimidine-5-carbonitrile (11a)
Yield 80% (1.2 g); yellow solid; mp 101–103°C; IR: 2964, 2839, 2229, 1585, 1535, 1450, 1348, 1213, 1031, 860 cm-1; 1H NMR: δ 8.82 (s, 1H), 7.74 (d, J = 3.2 Hz, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.50 (dd, J1 = 9.2 Hz, J2 = 3.2 Hz, 1H), 3.90 (s, 3H), 2.72 (s, 3H); HRMS (ESI): m/z calcd for C13 H11 N4 O4+ [M+H]+ 287.0775, found 287.0717.
4-Methyl-6-(4-methyl-2-nitrophenoxy)pyrimidine-5-carbonitrile (11b)
Yield 82% (2.1 g); brown solid; mp 102–104°C; 1H NMR: δ 8.80 (s, 1H), 8.09 (d, J =1.2 Hz, 1H), 7.73 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 2.73 (s, 3H), 2.50 (s, 3H); HRMS (ESI): m/z calcd for C13 H11 N4 O3+ [M+H]+ 271.0826, found 271.0804.
4-Methyl-6-(2-nitrophenoxy)pyrimidine-5-carbonitrile (11c)
Yield 79% (1.78 g); brown solid; mp 100–102°C; 1H NMR: δ 8.88 (s, 1H), 8.32 (dd, J1 = 8.4 Hz, J2 = 2 Hz, 1H), 8.01–7.97 (m, 1H), 7.75–7.70 (m, 2H), 2.79 (s, 3H); HRMS (ESI): m/z calcd for C12 H9 N4 O3+ [M+H]+ 257.0670, found 257.0671.
4-(4-Fluoro-2-nitrophenoxy)-6-methylpyrimidine-5-carbonitrile (11d)
Yield 76% (1.1 g); pale yellow solid; mp 126–128°C; 1H NMR: δ 8.84 (s, 1H), 8.23 (dd, J1 = 8.4 Hz, J2 = 2.0 Hz, 1H), 7.87–7.84 (m, 1H), 7.80–7.76 (m, 1H), 2.73 (s, 3H); HRMS (ESI): m/z calcd for C12 H8 N4 O3 F+ [M+H]+ 275.0575, found 275.0550.
4-(4-Chloro-2-nitrophenoxy)-6-methylpyrimidine-5-carbonitrile (11e)
Yield 78% (1.8 g); brown solid; mp 156–158°C; 1H NMR: δ 8.84 (s, 1H), 8.36 (d, J = 2.4 Hz, 1H), 8.02 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 7.75 (d, J = 8.8 Hz, 1H), 2.74 (s, 3H); HRMS (ESI): m/z calcd for C12 H8 N4 O3 Cl+ [M+H]+ 291.0280, found 291.0254.
4-(4-Bromo-2-nitrophenoxy)-6-methylpyrimidine-5-carbonitrile (11f)
Yield 65% (2.0 g); brown solid; mp 147–149°C; 1H NMR: δ 8.83 (s, 1H), 8.45 (d, J = 2.4 Hz, 1H), 8.15 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 2.73 (s, 3H); HRMS (ESI): m/z calcd for C12 H8 N4 O381Br+ and C12 H8 N4 O379Br+ [M+H]+ 336.9754 and 334.9775, found 336.9716 and 334.9745.
General procedure for the preparation of compounds 12a–f
A solution of 5-cyano-6-methylpyrimidines (11a–f) (5.88 mmol) and DMF-DMA (147 mmol) was heated under reflux at 130°C for 3.5 h. The reaction mixture was cooled and poured into ice water, and the resultant solid was filtered and dried under reduced pressure. The obtained products were used in the next step without further purification.
(E)-4-(2-(Dimethylamino)vinyl)-6-(4-methoxy-2-nitrophenoxy)pyrimidine-5-carbonitrile (12a)
Yield 79% (1.31 g); yellow solid; mp 165–167°C; 1H NMR: δ 8.24 (d, J = 11.6 Hz, 1H), 8.22 (s, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.42 (dd, J1 = 8.8 Hz, J2 = 2.8 Hz, 1H), 5.27 (d, J = 11.6 Hz, 1H), 3.88 (s, 3H), 3.22 (s, 3H), 2.97 (s, 3H); HRMS (ESI): m/z calcd for C16 H16 N5 O4+ [M+H]+ 342.1197, found 342.1130.
(E)-4-[2-(Dimethylamino)vinyl]-6-(4-methyl-2-nitrophenoxy)pyrimidine-5-carbonitrile (12b)
Yield 81% (400 mg); brown solid; mp 138–140°C; 1H NMR: δ 8.24 (d, J = 12 Hz, 1H), 8.20 (s, 1H), 8.02 (d, J = 1.2 Hz, 1H), 7.66 (dd, J1 = 8.4 Hz, J2 = 1.2 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 5.27 (d, J = 12 Hz, 1H), 3.22 (s, 3H), 2.97 (s, 3H), 1.43 (s, 3H); HRMS (ESI): m/z calcd for C16 H16 N5 O3+ [M+H]+ 326.1248, found 326.1308.
(E)-4-(2-(Dimethylamino)vinyl)-6-(2-nitrophenoxy)pyrimidine-5-carbonitrile (12c)
Yield 76% (1.25 g); brown solid; mp 157–159°C; 1H NMR: δ 8.25 (d, J = 12 Hz, 1H), 8.22 (s, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.89–7.85 (m, 1H), 7.63–7.57 (m, 2H), 5.29 (d, J = 12 Hz, 1H), 3.22 (s, 3H), 2.97 (s, 3H); HRMS (ESI): m/z calcd for C15 H14 N5 O3+ [M+H]+ 312.1091, found 312.1153.
(E)-4-(2-(Dimethylamino)vinyl)-6-(4-fluoro-2-nitrophenoxy)pyrimidine-5-carbonitrile (12d)
Yield 61% (790 mg); orange solid; mp 162–164°C; 1H NMR: δ 8.25 (d, J = 12.4 Hz, 1H), 8.23 (s, 1H), 8.17–8.14 (m, 1H), 7.80–7.78 (m, 1H), 7.77–7.70 (m, 1H), 5.29 (d, J = 12.4 Hz, 1H), 3.22 (s, 3H), 2.97 (s, 3H); HRMS (ESI): m/z calcd for C15 H13 N5 O3 F+ [M+H]+ 330.0997, found 330.1055.
(E)-4-(4-Chloro-2-nitrophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (12e)
Yield 58% (1.1 g); brown solid; mp 163–165°C; 1H NMR: δ 8.30 (d, J = 2.4 Hz, 1H), 8.25 (d, J = 11.6 Hz, 1H), 8.22 (s, 1H), 7.96 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 5.29 (d, J = 11.6 Hz, 1H), 3.22 (s, 3H), 2.97 (s, 3H); HRMS (ESI): m/z calcd for C15 H13 N5 O3 Cl+ [M+H]+ 346.0701, found 346.0769.
(E)-4-(4-Bromo-2-nitrophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (12f)
Yield 55% (1.2 g); yellow solid; mp 176–178°C; 1H NMR: δ 8.37 (d, J = 1.6 Hz, 1H), 8.25 (d, J = 12.4 Hz, 1H), 8.22 (s, 1H), 8.08 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 7.62 (d, J = 8.8 Hz, 1H), 5.28 (d, J = 12.4 Hz, 1H), 3.22 (s, 3H), 2.97 (s, 3H); HRMS (ESI): m/z calcd for C15 H13 N5 O381Br+ and C15 H13 N5 O379Br+ [M+H]+ 392.0176 and 390.0196, found 392.0213 and 390.0227.
General procedure for preparation of compounds 13a–f
To a solution of enamine (12a–f) (4.8 mmol) in dry THF (45 mL) was added anhydrous SnCl2 (24.2 mmol), and the mixture was heated under reflux under inert atmosphere for 6 h. The mixture was cooled and poured into ice-cold water and basified with saturated aqueous sodium carbonate to ∼pH 9. The basic aqueous mixture was extracted with ethyl acetate three times. The extract was washed with water, dried over anhydrous Na2 SO4, and concentrated reduced pressure. The pure product was obtained by column chromatography on silica gel (100–200 mesh) eluting with 1–2% (v/v) methanol in dichloromethane.
(E)-4-(2-Amino-4-methoxyphenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13a)
Yield 78% (800 mg); pale yellow solid; mp 249–251°C; IR: 3365, 2945, 2196, 1620, 1571, 1523, 1402, 1288, 1203, 1020, 867, 792 cm-1; 1H NMR: δ 9.56 (s, 1H), 8.29 (s, 1H), 8.13 (s, 1H), 8.08 (d, J = 12 Hz, 1H), 7.72 (d, J = 2.8 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 6.54 (dd, J1 = 8.8 Hz, J2 = 2.8 Hz, 1H), 5.17 (d, J = 12 Hz, 1H), 3.67 (s, 3H), 3.15 (br s, 3H), 2.90 (br s, 3H); 13C NMR: δ 165.7, 159.9, 157.9, 152.0, 150.9, 141.5, 127.0, 116.1, 115.1, 108.7, 108.6, 89.4, 80.1, 54.9, 44.6 (2C); HRMS (ESI): m/z calcd for C16 H18 N5 O2+ [M+H]+ 312.14550, found 312.14500.
(E)-4-(2-Amino-4-methylphenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13b)
Yield 77% (80 mg); yellow solid; mp 260–262°C; IR: 3379, 2914, 2198, 1620, 1577, 1535, 1402, 1288, 1215, 1109, 866, 792 cm-1; 1H NMR: δ 9.72 (s, 1H), 8.26 (s, 1H), 8.14 (s, 1H), 8.08 (d, J = 12 Hz, 1H), 7.75 (s, 1H), 6.77 (s, 2H), 5.16 (d, J = 12 Hz, 1H), 3.14 (br s, 3H), 2.90 (br s, 3H), 2.20 (s, 3H); 13C NMR: δ 165.7, 160.1, 157.9, 150.8, 146.0, 127.5, 126.0, 124.9, 123.3, 116.2, 114.8, 89.4, 79.6, 54.9, 44.6 (2C); HRMS (ESI): m/z calcd for C16 H18 N5 O+ [M+H]+ 296.15059, found 296.15014.
(E)-4-(2-Aminophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13c)
Yield 75% (700 mg); pale brown solid; mp 256–258°C; IR: 3379, 2912, 2198, 1631, 1573, 1517, 1454, 1286, 1217, 1118, 1014, 792 cm-1; 1H NMR: δ 9.96 (s, 1H), 8.24 (s, 1H), 8.19 (s, 1H), 8.08 (d, J = 12 Hz, 1H), 7.90 (d, J = 8 Hz, 1H), 6.99–6.78 (m, 3H), 5.17 (d, J = 12 Hz, 1H), 3.13 (br s, 3H), 2.91 (br s, 3H); 13C NMR: δ 165.8, 160.2, 157.9, 150.8, 148.4, 126.2, 124.6, 123.2, 118.9, 116.2, 115.1, 89.4, 80.0, 44.6 (2C); HRMS (ESI): m/z calcd for C15 H16 N5 O+ [M+H]+ 282.13494, found 282.13432.
(E)-4-(2-Amino-4-fluorophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13d)
Yield 74% (450 mg); pale yellow solid; mp 268–270°C; IR: 3371, 2945, 2200, 1620, 1573, 1523, 1402, 1288, 1203, 1116, 869, 794 cm-1; 1H NMR: δ 10.13 (s, 1H), 8.32 (s, 1H), 8.12 (s, 1H), 8.08 (d, J = 12 Hz, 1H), 8.03–8.01 (m, 1H), 6.88–6.84 (m, 1H), 6.79–6.75 (m, 1H), 5.17 (d, J = 12 Hz, 1H), 3.16 (br s, 3H), 2.91 (br s, 3H); 13C NMR: δ 165.7, 159.8, 158.8, 156.8, 153.8, 151.9, 150.2, 143.5, 127.2, 116.0, 114.1, 108.5, 90.24, 88.6, 80.3; HRMS (ESI): m/z calcd for C15 H15 N5 OF+ [M+H]+ 300.12551, found 300.12499.
(E)-4-(2-Amino-4-chlorophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13e)
Yield 68% (330 mg); pale yellow solid; mp 274–276°C; IR: 3362, 2942, 2190, 1620, 1573, 1523, 1402, 1287, 1202, 1020, 868, 792 cm-1; 1H NMR: δ 10.41 (s, 1H), 8.32 (s, 1H), 8.14 (m, 2H), 8.08 (d, J = 12 Hz, 1H), 6.98 (dd, J1 = 8.4 Hz, J2 =2.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 5.17 (d, J = 12 Hz, 1H), 3.16 (br s, 3H), 2.91 (br s, 3H); 13C NMR: δ 165.7, 159.9, 157.9, 151.0, 146.7, 127.6, 123.5, 122.2, 121.5, 116.0, 115.9, 89.4, 80.3, 44.6 (2C); HRMS (ESI): m/z calcd for C15 H15 N5 OCl+ [M+H]+ 316.09596, found 316.09538.
(E)-4-(2-Amino-4-bromophenoxy)-6-(2-(dimethylamino)vinyl)pyrimidine-5-carbonitrile (13f)
Yield 62% (500 mg); pale brown solid; mp 264–266°C; IR: 3371, 2931, 2198, 1631, 1571, 1514, 1396, 1286, 1112, 1018, 871, 796 cm-1; 1H NMR: δ 10.43 (s, 1H), 8.31 (s, 1H), 8.24 (d, J = 2.4 Hz, 1H), 8.15 (s, 1H), 8.10 (d, J = 12 Hz, 1H), 7.11 (dd, J1 = 8.8 Hz, J2 = 2.4 Hz, 1H), 6.84 (d, J = 8.8 Hz, 1H), 5.17 (d, J = 12 Hz, 1H), 3.16 (br s, 3H), 2.90 (br s, 3H); 13C NMR: δ 165.7, 159.9, 156.9, 151.9, 150.2, 147.2, 127.3, 125.6, 123.5, 117.3, 116.0, 90.2, 80.3, 44.6 (2C); HRMS (ESI): m/z calcd for C15 H15 N5 O81Br+ and C15 H15 N5 O79Br+ [M+H]+ 362.0439 and 360.0454, found 362.0444 and 360.0485.
General procedure for preparation of compounds 14a–f
To a solution of enamine 12a–f (4.8 mmol) in dry THF (45 mL) was added SnCl2×2H2 O (24.2 mmol), and the reaction mixture was heated under reflux under inert atmosphere for 18 h. The mixture was cooled and poured into ice-cold water and basified with saturated aqueous sodium carbonate to ∼pH 9. The basic aqueous mixture was extracted with ethyl acetate three times. The ethyl acetate layers were pooled, washed with water, dried over anhydrous Na2 SO4, and concentrated under reduced pressure. The pure product was obtained by column chromatography on silica gel (100–200 mesh) eluting with 1–2% (v/v) methanol in dichloromethane.
4-(2-Amino-4-methoxyphenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14a)
Yield: 73% (32 mg), brown solid; mp 172–174°C. IR: 3057, 1585, 1512, 1265, 1205, 1116, 829 cm-1; 1H NMR: δ 12.04 (s, 1H), 11.91 (d, J = 6 Hz, 1H), 9.59 (s, 1H), 8.65 (s, 1H), 8.34 (d, J = 3.2 Hz, 1H), 7.59 (t, J = 6 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 6.53 (dd, J1 = 8.8 Hz, J2 = 3.2 Hz, 1H), 6.43 (d, J = 6 Hz, 1H), 3.70 (s, 3H); 13C NMR: δ 163.0, 160.0, 159.9, 158.8, 151.8, 141.0, 137.0, 127.4, 114.6, 108.3, 107.7, 105.7, 104.1, 55.3; HRMS (ESI): m/z calcd for C14 H12 N4 NaO3+ [M+Na]+ 307.0802, found 307.0815.
4-(2-Amino-4-methylphenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14b)
Yield 70% (100 mg); pale brown solid; mp 308–310°C; IR: 3147, 1649, 1587, 1502, 1224, 831 cm-1; 1H NMR: δ 11.96 (s, 1H), 11.89 (d, J = 6 Hz, 1H), 9.81 (s, 1H), 8.63 (s, 1H), 8.39 (d, J = 1.6 Hz, 1H), 7.59 (t, J = 6 Hz, 1H), 6.8 (d, J = 8.4 Hz, 1H), 6.74 (dd, J1 = 8.4 Hz, J2 = 1.6 Hz, 1H), 6.42 (d, J = 6 Hz, 1H), 2.24 (s, 3H); 13C NMR: δ 163.0, 160.1, 159.9, 158.9, 145.1, 136.9, 127.3, 126.5, 124.1, 122.0, 114.4, 105.7, 104.0, 20.7; HRMS (ESI): m/z calcd for C14 H13 N4 O2+ [M+H]+ 269.10330, found 269.10277.
4-(2-Aminophenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14c)
Yield 72% (116 mg); pale brown solid; mp 323–325°C; IR: 3062, 1658, 1610, 1583, 1460, 1269, 1107, 829, 746 cm-1; 1H NMR: δ 12.00 (s, 1H), 11.90 (d, J = 4.4 Hz, 1H), 10.07 (s, 1H), 8.62 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 6.4 Hz, 1H), 6.94–6.92 (m, 2H), 6.85–6.83 (m, 1H), 6.43 (d, J = 6.8 Hz, 1H); 13C NMR: δ 163.1, 160.0 (2C), 158.9, 147.3, 136.9, 126.7, 123.8, 121.6, 118.8, 114.6, 105.7, 104.1; HRMS (ESI): m/z calcd for C13 H11 N4 O2+ [M+H]+ 255.0877, found 255.0897.
4-(2-Amino-4-fluorophenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14d)
Yield: 65% (30 mg); yellow solid; mp 318–320°C; IR: 3111, 2717, 1649, 1571, 1502, 1444, 1274, 1257, 1192, 966, 833 cm-1; 1H NMR: δ 12.16 (s, 1H), 11.94 (d, J = 5.2 Hz, 1H), 10.13 (s, 1H), 8.70 (s, 1H), 8.59 (dd, J1 = 11.6 Hz, J2 = 2.8 Hz, 1H), 7.62 (t, J = 6.8 Hz, 1H), 6.90–6.87 (m, 1H), 6.77–6.75 (m, 1H), 6.45 (d, J = 6.8 Hz, 1H); 13C NMR: δ 163.0, 159.9, 158.9, 155.9, 143.2, 137.2, 127.7, 114.5, 109.0, 108.1, 107.8, 105.7, 104.2; HRMS (ESI): m/z calcd for C13 H10 N4 O2 F+ [M+H]+ 273.0782, found 273.0807.
4-(2-Amino-4-chlorophenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14e)
Yield 55% (200 mg); yellow solid; mp 326–328°C; IR: 3018, 2852, 1666, 1606, 1579, 1427, 1280, 1120, 885, 829 cm-1; 1H NMR: δ 12.14 (s, 1H), 11.91 (d, J = 5.2 Hz, 1H), 10.45 (s, 1H), 8.78 (d, J = 2.4 Hz, 1H), 8.71 (s, 1H), 7.62 (t, J = 6.4 Hz, 1H), 6.99–6.91 (m, 2H), 6.45 (d, J = 6.8 Hz, 1H); 13C NMR: δ 163.0, 160.0, 159.9, 158.9, 145.9, 137.1, 128.1, 122.8, 122.1, 120.3, 115.5, 105.8, 104.2; HRMS (ESI): m/z calcd for C13 H10 N4 O2 Cl+ [M+H]+ 289.04868, found 289.04864.
4-(2-Amino-4-bromophenoxy)pyrido[4,3-d]pyrimidin-5(6H)-one (14f)
Yield 45% (100 mg); yellow solid; mp 314–316°C; IR: 3012, 2868, 1664, 1604, 1575, 1423, 1278, 1120, 879, 829 cm-1; 1H NMR: δ 12.14 (s, 1H), 11.96 (d, J = 5.6 Hz, 1H), 10.48 (s, 1H), 8.90 (d, J = 2.4 Hz, 1H), 8.71 (s, 1H), 7.62 (t, J = 6.4 Hz, 1H), 7.10 (dd, J1 = 8.4 Hz, J2 = 2.4 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.45 (d, J = 7.2 Hz, 1H); 13C NMR: δ 163.0, 160.0, 159.9, 158.9, 146.4, 137.1, 128.5, 125.7, 123.1, 116.0, 109.8, 105.8, 104.2; HRMS (ESI): m/z calcd for C13 H10 N4 O281Br+ and C13 H10 N4 O279Br+ [M+H]+ 334.9967 and 332.99816, found 334.99610 and 332.99816.
Acknowledgments
The authors thank Aurigene Discovery Technologies Ltd. for financial support and Jawaharlal Nehru Technological University for encouragement. The cooperation extended from the analytical department in recording spectral data is gratefully acknowledged.
References
[1] Bilodeau, M. T.; Balitza, A. E.; Koester, T. J.; Manley, P. J.; Rodman, L. D.; Doepner, C. B.; Coll, K. E.; Fernandes, C.; Gibbs, J. B.; Heimbrook, D. C.; et al. Potent N-(1,3-thiazol-2-yl) pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. J. Med. Chem.2004, 47, 6363–6372.Search in Google Scholar
[2] Deng, X.; Yang, Q.; Kwiatkowski, N.; Sim, T.; McDermott, U.; Settleman, J. E.; Lee, J. D.; Gray, N. S. Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med. Chem. Lett.2011, 2, 195–200.Search in Google Scholar
[3] Sum, F. -W.; Dusza, J.; Santos, E. D.; Grosu, G.; Reich, M.; Du, X.; Albright, J. D.; Chan, P.; Coupet, J.; Ru, X.; et al. Structure-activity study of novel tricyclic benzaazepine arginine vasopressin antagonists. Bioorg. Med. Chem. Lett.2003, 13, 2195–2198.Search in Google Scholar
[4] Grant, S. M.; Faulds, D. Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs1992, 43, 873–888.Search in Google Scholar
[5] Calligaro, D. O.; Fairhurst, J.; Hotten, T. M.; Moore, N. A.; Tupper, D. E. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053). Bioorg. Med. Chem. Lett.1997, 7, 25–30.Search in Google Scholar
[6] Sasikumar, T. K.; Burnett, D. A.; Zhang, H.; Torhan, A. S.; Fawzi, A.; Lachowicz, J. E. Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 4543–4547.Search in Google Scholar
[7] Mink, K.; Bracher, F. Hetero analogues of the antimicrobial alkaloids cleistopholine and sampangine. Arch. Pharm. Chem. Life Sci. 2007, 340, 429–433.Search in Google Scholar
[8] Basetti, V.; Pallepati, R.; Hosahalli, S.; Potluri, V. A facile synthesis of tetracyclic benzo-pyridonaphthyridines by domino reaction. Tetrahedron Lett. 2013, 54, 2014–2017.Search in Google Scholar
[9] Mittelbach, M.; Junek, H. Synthesen mit Nitrilen,LVII[1] Zur Reaktivitat von Aminomethylen-malonsauredinitrilen gegenuber Aldehyden und orthoestern. Z. Naturforsch. Teil B. 1979, 34, 1580–1586.Search in Google Scholar
[10] Kuragano, T.; Tanaka, Y. Sumitomo Chemical Takeda Agro Company. Pyrimidine derivatives and herbicides containing the same. European Patent Application EP 1333029A1, 2003.Search in Google Scholar
[11] El-Reddy, A. M.; Ali, A. S.; Ayaad, A. O. Azolopyrimidines and pyrimidoquinazolinesfrom 4-chloropyrimidines. J. Heterocycl. Chem.1989, 26, 313–316.Search in Google Scholar
[12] Baldwin, J. J.; Mensler, K.; Ponticello, G. S. A novel naphthyridinone synthesis via enamine cyclization. J. Org. Chem. 1978, 43, 4878–4880.Search in Google Scholar
[13] Sureshbabu, R.; Balamurugan, R.; Mohanakrishnan, A. K. Synthesis of substituted carbazoles via electrocyclization of in situ generated enamines from 1-phenylsulfonyl-2/(3)-methyl-3/(2)-vinylindoles and DMF.DMA/DMA.DMA. Tetrahetrdon2009, 65, 3582–3591.Search in Google Scholar
[14] Gritsenko, R. T.; Levin, V. V.; Dilman, A. D.; Belyakov, P. A.; Struchkova, M. I.; Tartakovsky, V. A. Trifluoromethylation of enamines under acidic conditions. Tetrahedron Lett. 2009, 50, 2994–2997.Search in Google Scholar
[15] Reid, W.; Beller, G. Reaction of chloropyrimidine. II. Synthesis of new diazepines and azaphenalenes from pyrrolo[3,4-d]pyrimidines. Justus Liebigs Ann. Chem. 1988, 7, 643–648.Search in Google Scholar
©2014 by De Gruyter
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Articles in the same Issue
- Frontmatter
- Preliminary Communication
- A novel synthetic approach to 11-substituted dibenzo[b,f][1,4]oxazepines
- Research Articles
- Cyclopropyl aziridines: solvolytic reactions of the N-tosylaziridines of (+)-2-carene and (+)-3-carene
- Synthesis and crystal structural characterization of two new 3,5-disubstituted 4-amino-1,2,4-triazoles
- A facile synthesis of 7,12-dihydro-1,3,6,7,12-pentaazapleiadenes by domino reaction
- New derivatives of 4,6-dimethylisoxazolo[3,4-b] pyridin-3(1H)-one: synthesis, tautomerism, electronic structure and antibacterial activity
- Synthesis and antimicrobial evaluation of purine substituted N-acyl-α-carboxamides via the Ugi four-component reaction
- Facile synthesis of substituted dihydro-1H-pyrazolo[3,4-d]thiazoles through enaminones of 4-thiazolidinones
- Multi-component synthesis of 1,2-diphenyl-2-[2-(5-aryl-6H-1,3,4-thiadiazin-2-yl)hydrazono]ethanone
- Ab initio study of mechanism of forming a spiro-Si-heterocyclic compound involving Ge from (CH3)2Ge=Si: and formaldehyde
Articles in the same Issue
- Frontmatter
- Preliminary Communication
- A novel synthetic approach to 11-substituted dibenzo[b,f][1,4]oxazepines
- Research Articles
- Cyclopropyl aziridines: solvolytic reactions of the N-tosylaziridines of (+)-2-carene and (+)-3-carene
- Synthesis and crystal structural characterization of two new 3,5-disubstituted 4-amino-1,2,4-triazoles
- A facile synthesis of 7,12-dihydro-1,3,6,7,12-pentaazapleiadenes by domino reaction
- New derivatives of 4,6-dimethylisoxazolo[3,4-b] pyridin-3(1H)-one: synthesis, tautomerism, electronic structure and antibacterial activity
- Synthesis and antimicrobial evaluation of purine substituted N-acyl-α-carboxamides via the Ugi four-component reaction
- Facile synthesis of substituted dihydro-1H-pyrazolo[3,4-d]thiazoles through enaminones of 4-thiazolidinones
- Multi-component synthesis of 1,2-diphenyl-2-[2-(5-aryl-6H-1,3,4-thiadiazin-2-yl)hydrazono]ethanone
- Ab initio study of mechanism of forming a spiro-Si-heterocyclic compound involving Ge from (CH3)2Ge=Si: and formaldehyde